Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ME Therapeutics Holdings, Inc. ( (TSE:METX) ) has issued an announcement.
ME Therapeutics Holdings Inc. announced that its subsidiary is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to advance its mRNA therapeutic program. This initiative aims to develop treatments targeting myeloid cell biology for cancer and inflammatory diseases, with promising preclinical results in colorectal cancer models, potentially enhancing the company’s position in the immuno-oncology field.
More about ME Therapeutics Holdings, Inc.
Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver, focused on discovering and developing novel immuno-oncology therapeutics. The company targets immune suppression in cancer by overcoming the suppressive effects of myeloid cells to enhance anti-cancer immunity.
Average Trading Volume: 300
Technical Sentiment Signal: Buy
See more data about METX stock on TipRanks’ Stock Analysis page.